Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy

Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica J., Kayani, Jehanzeb, Fisher, Ann, Kotansky, Brian, Dembry, Louise-Marie, Datta, Rupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726471/
https://www.ncbi.nlm.nih.gov/pubmed/36483361
http://dx.doi.org/10.1017/ash.2022.229
_version_ 1784844793236422656
author Tuan, Jessica J.
Kayani, Jehanzeb
Fisher, Ann
Kotansky, Brian
Dembry, Louise-Marie
Datta, Rupak
author_facet Tuan, Jessica J.
Kayani, Jehanzeb
Fisher, Ann
Kotansky, Brian
Dembry, Louise-Marie
Datta, Rupak
author_sort Tuan, Jessica J.
collection PubMed
description Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died.
format Online
Article
Text
id pubmed-9726471
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-97264712022-12-07 Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy Tuan, Jessica J. Kayani, Jehanzeb Fisher, Ann Kotansky, Brian Dembry, Louise-Marie Datta, Rupak Antimicrob Steward Healthc Epidemiol Concise Communication Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died. Cambridge University Press 2022-05-20 /pmc/articles/PMC9726471/ /pubmed/36483361 http://dx.doi.org/10.1017/ash.2022.229 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction in any medium, provided the original article is properly cited.
spellingShingle Concise Communication
Tuan, Jessica J.
Kayani, Jehanzeb
Fisher, Ann
Kotansky, Brian
Dembry, Louise-Marie
Datta, Rupak
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title_full Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title_fullStr Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title_full_unstemmed Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title_short Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
title_sort clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
topic Concise Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726471/
https://www.ncbi.nlm.nih.gov/pubmed/36483361
http://dx.doi.org/10.1017/ash.2022.229
work_keys_str_mv AT tuanjessicaj clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy
AT kayanijehanzeb clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy
AT fisherann clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy
AT kotanskybrian clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy
AT dembrylouisemarie clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy
AT dattarupak clinicaloutcomesfollowingdalbavancinadministrationinpatientswithbarrierstooutpatientparenteralantimicrobialtherapy

Ejemplares similares